Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 4. Cryptogenic Organizing Pneumonia
Article information
Abstract
Cryptogenic organizing pneumonia (COP) is a type of idiopathic interstitial pneumonia with an acute or subacute clinical course. Bilateral lung consolidations located in the subpleural area and bronchovascular bundle are the most common findings on chest high-resolution computed tomography. The pathologic manifestations include granulation tissue in the alveoli, alveolar ducts, and bronchioles. COP responds fairly well to glucocorticoid monotherapy with rapid clinical improvement, but recurrence is common. However, treatment with combined immunosuppressant agents is not recommended, even if the COP patient does not respond to glucocorticoid monotherapy with expert opinion.
Introduction
Cryptogenic organizing pneumonia (COP) is a disease entity and a type of idiopathic interstitial pneumonia (IIP). COP was previously designated as bronchiolitis obliterans organizing pneumonia (BOOP), but the BOOP nomenclature has since been discarded to avoid a misleading association with airway disease1,2. The differential diagnosis of COP from other etiologies is confirmed by identifying the organizing pneumonia pattern on lung biopsy.
1. History
COP was first described in the 1980s by Davison et al.3 and Epler et al.4 as COP and BOOP, respectively. They described an illness similar to the common cold, but which (1) subacutely progressed for 4–10 weeks, (2) histologically showed intra-alveolar and alveolar duct consolidation, (3) responded fairly well to glucocorticosteroid therapy, and (4) frequently recurred. In 1997, Muller and Coiby5 classified idiopathic BOOP as an independent disease among IIPs according to chest high-resolution computed tomography (HRCT) and pathologic findings. In 2002, the American Thoracic Society (ATS) and European Respiratory Society (ERS) categorized COP as a form of IIP different from idiopathic pulmonary fibrosis. Specifically, the ATS/ERS classification system recommended using the term COP, as BOOP could be erroneously misclassified as an airway disease and may not histologically present with bronchiolitis obliterans1. The revised 2013 ATS/ERS classification used the term COP instead of BOOP and defined the disease as having an acute or subacute course. COP and BOOP have been used simultaneously for some time, and some studies employed the term “idiopathic BOOP” to differentiate illnesses of unknown etiology from other illnesses with secondary causes.
2. Epidemiology
To the best of our knowledge, there have been no studies on the prevalence or incidence of COP. However, several retrospective cohort studies have estimated a COP incidence of 1.1 cases per 100,000 persons6. The prevalence was estimated at 3% among patients with interstitial lung disease (ILD), including those with connective tissue disease-related ILD and idiopathic ILD7. According to a 2008 national study by the Korean Academy of Tuberculosis and Respiratory Diseases, COP was detected in 8.5% of 2,186 IIP subjects and was the third most common disease among them8. COP usually occurs in the sixth and seventh decades of life. COP appears to have no distinct predilection according to sex. Although there have been some discrepancies among previous reports, nonsmokers were more common among COP patients than current smokers1,6,9–11.
Clinical Manifestation and Diagnosis
1. Clinical manifestation
Previous studies have shown that the symptoms of COP lasted for less than three months on average, and followed an acute or subacute course. COP patients typically present with cough, dyspnea, and fever, and crackles are commonly heard on auscultation, whereas wheezing lung sounds are rarely noted. On pulmonary function tests, restrictive ventilatory defects and a decrease in the carbon monoxide diffusing capacity (DLCO) are typically observed10,12–15. However, the manifestations of organizing pneumonia can be seen in several conditions, such as infectious lung disease, inflammatory bowel disease, connective tissue disease, myeloproliferative disorder, graft-versus-host disease, drug reactions, or after undergoing radiation therapy. Of note, about half of the IIP patients were initially diagnosed with infectious lung disease and unsuccessfully treated with antibiotics; they were not correctly diagnosed until a lung biopsy was obtained12,16. Patients with infectious lung disease often present with similar clinical manifestations, such as cough, dyspnea, fever, general weakness, and chest computed tomography showing parenchymal consolidation, which obscures the differential diagnosis. One study reported that various bacteria, such as Streptococcus pneumoniae, Mycoplasma pneumoniae, Pseudomonas, Legionella, Pneumocystis jiroveci, and Nocardia, can cause organizing pneumonia13. Additionally, hypersensitivity pneumonitis, IIPs, and chronic eosinophilic pneumonitis are often accompanied by COP, requiring a thorough diagnostic evaluation. Therefore, when COP is suspected, careful history-taking is needed to differentially evaluate infectious, drug-induced, or any other etiologies. Furthermore, a multidisciplinary approach involving a pulmonologist, radiologist, and pathologist is necessary2. A comprehensive differential diagnosis is shown in Table 1.
2. Pulmonary function test
A restrictive ventilator defect is common in COP and the forced vital capacity is decreased mildly or moderately from 60% to 70%. However, an obstructive component (with a restrictive pattern) can also accompany the common symptoms or can occur in isolation in 10–30% of the patients. A DLCO decrease of 50%–70% is occasionally observed9,12–14.
3. Radiologic findings
On chest HRCT, consolidation along the subpleural area and bronchovascular bundle was the most common finding and was noted in nearly half of the cases, mostly bilaterally, and usually invaded the lower portion of the lungs9,12,14,16–18. Ground-glass opacity (GGO) is also frequently seen with an irregular distribution and concomitant consolidation, but sometimes is the sole feature19,20. Alternatively, perilobular opacity and a reversed halo sign (where the central GGO is surrounded by consolidation) were noted in 57% and 20% of patients, respectively21. Consolidation can appear as a unifocal or cavitary shape and rarely, as a large nodule or mass. Honeycombing or reticular lesions are rare. Some pulmonary lesions can migrate or even resolve spontaneously during follow-up. One retrospective study from Korea showed consolidation and GGO as the most common findings, mostly involving the lower lungs (Figure 1)20.
4. Bronchoscopy
Bronchoalveolar lavage fluid analysis showed that the lymphocytic fraction increased by more than 25% in most cases, and some subjects showed a decrease in the CD4/CD8 ratio, but these findings were nonspecific and played an auxiliary role in differential diagnosis10,11,22. Specifically, an elevated neutrophilic fraction requires discrimination from organizing pneumonia with an infectious etiology.
5. Lung biopsy
Lung biopsy is essential for confirmative diagnosis. Granulation tissue with Masson’s bodies noted in the alveoli, alveolar duct, and some bronchioles are typical findings (Figure 2). In some cases, polyps are also present in the bronchiolar lumen. These characteristics indicate organizing pneumonia a finding seen with a patchy distribution, but structural deformities occur only infrequently. Interstitial fibrosis, granuloma, necrosis, vasculitis, and hyaline membrane are rare and suggest other underlying disorders1,23. Biopsy via surgery is the diagnostic standard. While transbronchial lung biopsy (TBLB) is not recommended for other IIPs, studies have shown some potential of TBLB in diagnosing COP, despite the limitation that the number of biopsy specimens was insufficient in most cases9,10,14–16,18.
Treatment
There have been no studies comparing glucocorticoid monotherapy and placebo for COP treatment. However, several studies have reported rapid clinical improvement after glucocorticoid steroid treatment. The starting dosage for methylprednisolone or prednisone ranges from 0.5–1 mg/kg, with gradual tapering after a few weeks10,14,17. There is no established treatment duration, but six months to one year is recommended9,24. Recurrence is frequent, with a rate ranging from 13% to 58%, and is associated with delayed glucocorticosteroid management9, insufficient glucocorticosteroid dosage, and short glucocorticosteroid treatment duration11. Nevertheless, the therapeutic response to glucocorticosteroids after recurrence is still favorable. According to Lazor et al.9, retreatment after recurrence with a dosage of <20 mg/day with an increase to 20 mg/day or higher (e.g., average 40 mg/day) yielded similar clinical outcomes, but complications were more frequent as the dosage increased, suggesting that a retreatment dose of 20 mg/day with gradual tapering is the optimal management strategy. Macrolide antibiotics25–27 and several immunosuppressants, such as cyclophosphamide13,28, cyclosporine29, and azathioprine, have been introduced as glucocorticosteroid-sparing agents, but their efficacy is unknown, and only case reports of these treatments have been presented.
Natural Course and Prognosis
The response to glucocorticosteroids is generally good, and most COP cases resolve completely, but the recurrence rate is considerably high. Lazor et al.9 reported that 58% of the patients with COP experienced recurrence after glucocorticosteroid treatment, and 27% had more than two recurrence episodes. Most patients experienced recurrence within one year, and the most important factor predicting recurrence was a delay of >16 weeks after symptom development. A study by Cazzato et al.11, which also included secondary interstitial pneumonia cases, found that 26% of the patients had a verified recurrence, and patients who received a lower glucocorticosteroid dose or a shorter administration period were more susceptible to recurrence. Non-responsiveness to glucocorticosteroid treatment occurred in 12%–22% of patients with COP. However, the likelihood of the rapid progression to respiratory failure or death was rare (<5%)10,11,22.
Notes
Authors’ Contributions
Conceptualization: Choi SI, Lee EJ. Methodology: Choi SI, Lee EJ. Formal analysis: Choi SI, Lee EJ, Jung WJ. Writing - original draft preparation: Choi SI, Lee EJ. Writing - review and editing: Jung WJ. Approval of final manuscript: all authors.
Conflicts of Interest
No potential conflict of interest relevant to this article was reported.
Funding
No funding to declare.